Document is current
Any future updates will be listed below
-
Authors
Wanders, Johanna O. P.
van Gils, Carla H.
Karssemeijer, Nico
Holland, Katharina
Kallenberg, Michiel
Peeters, Petra H. M.
Nielsen, Mads
Lillholm, Martin
-
Funding
Funding for this research was provided by:
European Union’s Seventh Framework Programme (306088)
KWF Kankerbestrijding (KWF UU 2009-4348)
- License Information
-
More Information
Article History
Received: 16 July 2017
Accepted: 21 March 2018
First Online: 2 May 2018
Ethics approval and consent to participate
: By participating in the Dutch screening program, women consent to their data being used for evaluation and improvement of the screening, unless they have indicated otherwise. The research ethics committee of the Radboud University Nijmegen Medical Centre declared that this study does not fall within the remit of the Medical Research Involving Human Subjects Act. Therefore, this study could be carried out (in The Netherlands) without approval by an accredited research ethics committee.
: The four mammograms in Fig. InternalRef removed are from four women who participated in the Dutch breast cancer screening program. As we received anonymized data, we do not know to whom these mammograms belong and therefore we cannot ask the women for consent. In addition, the mammograms do not contain any information that can identify the women to whom the mammograms belong.
: CvG reports a grant from Bayer Healthcare, and non-financial support from Volpara Solutions outside the submitted work. NK reports being one of the co-founders of Volpara Solutions, which develops and markets the breast density measurement software, Volpara, used in this study. In addition, NK has a patent pending and is co-founder of two other companies in the field of breast imaging next to his position as professor in the University. The two companies are Qview Medical (Los, Altos, CA, USA), and ScreenPoint Medical (Nijmegen, the Netherlands). These companies develop products for computer-aided detection of breast cancer, in whole breast ultrasound and in mammography respectively. MN and ML both report having shares in Biomediq A/S; this company developed the texture pattern score which is used in this study. The other authors (JW, KH, MK, and PP) declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
